130 related articles for article (PubMed ID: 8877491)
21. Assessment of nonischemic fibrosis in hypertrophic cardiomyopathy: comparison of gadopentetate dimeglumine and gadobenate dimeglumine for enhanced cardiovascular magnetic resonance imaging.
Rudolph A; von Knobelsdorff-Brenkenhoff F; Wassmuth R; Prothmann M; Utz W; Schulz-Menger J
J Magn Reson Imaging; 2014 May; 39(5):1153-60. PubMed ID: 24151119
[TBL] [Abstract][Full Text] [Related]
22. Gadobenate dimeglumine-enhanced MRI of the breast: analysis of dose response and comparison with gadopentetate dimeglumine.
Knopp MV; Bourne MW; Sardanelli F; Wasser MN; Bonomo L; Boetes C; Müller-Schimpfle M; Hall-Craggs MA; Hamm B; Orlacchio A; Bartolozzi C; Kessler M; Fischer U; Schneider G; Oudkerk M; Teh WL; Gehl HB; Salerio I; Pirovano G; La Noce A; Kirchin MA; Spinazzi A
AJR Am J Roentgenol; 2003 Sep; 181(3):663-76. PubMed ID: 12933457
[TBL] [Abstract][Full Text] [Related]
23. Histologic abnormalities associated with gadolinium enhancement on MR in the initial hours of experimental cerebral infarction.
Mathews VP; Monsein LH; Pardo CA; Bryan RN
AJNR Am J Neuroradiol; 1994 Mar; 15(3):573-9. PubMed ID: 8197960
[TBL] [Abstract][Full Text] [Related]
24. Tolerance of extracellular contrast agents for magnetic resonance imaging.
Weinmann HJ; Press WR; Gries H
Invest Radiol; 1990 Sep; 25 Suppl 1():S49-50. PubMed ID: 2283256
[No Abstract] [Full Text] [Related]
25. Triple-dose versus standard-dose gadopentetate dimeglumine: a randomized study in 199 patients.
Haustein J; Laniado M; Niendorf HP; Louton T; Beck W; Planitzer J; Schöffel M; Reiser M; Kaiser W; Schörner W
Radiology; 1993 Mar; 186(3):855-60. PubMed ID: 8430199
[TBL] [Abstract][Full Text] [Related]
26. Magnetic resonance imaging detection of extraluminal enterally administered gadopentetate dimeglumine in a rat model of intestinal ischemia.
Montalbano JM; Lee FT; Grist TM; Rappe AH; Weiss JW; Kelcz F; Gribenko V
Acad Radiol; 1996 Jun; 3(6):486-92. PubMed ID: 8796706
[TBL] [Abstract][Full Text] [Related]
27. Gadobenate dimeglumine (MultiHance) in MR angiography: an in-vitro phantom comparison with gadopentetate dimeglumine (Magnevist) at different concentrations.
Johansson L; Kirchin MA; Ahlström H
Acta Radiol; 2012 Dec; 53(10):1112-7. PubMed ID: 23081961
[TBL] [Abstract][Full Text] [Related]
28. Gadolinium Retention, Brain T1 Hyperintensity, and Endogenous Metals: A Comparative Study of Macrocyclic Versus Linear Gadolinium Chelates in Renally Sensitized Rats.
Rasschaert M; Emerit A; Fretellier N; Factor C; Robert P; Idée JM; Corot C
Invest Radiol; 2018 Jun; 53(6):328-337. PubMed ID: 29329151
[TBL] [Abstract][Full Text] [Related]
29. Double-blind, efficacy evaluation of gadobenate dimeglumine, a gadolinium chelate with enhanced relaxivity, in malignant lesions of the brain.
Runge VM; Parker JR; Donovan M
Invest Radiol; 2002 May; 37(5):269-80. PubMed ID: 11979153
[TBL] [Abstract][Full Text] [Related]
30. Magnetic resonance imaging contrast media in the subarachnoid space. A comparison between gadodiamide injection and gadopentetate dimeglumine in an experimental study in pigs.
Skalpe IO; Tang GJ
Invest Radiol; 1997 Mar; 32(3):140-8. PubMed ID: 9055126
[TBL] [Abstract][Full Text] [Related]
31. Neurotoxicity of contrast media for magnetic resonance imaging after generalized breakdown of the blood-brain barrier.
Evill CA; Wilson AJ; Fletcher MC; Sage MR
Acad Radiol; 1996 Aug; 3 Suppl 2():S336-8. PubMed ID: 8796597
[No Abstract] [Full Text] [Related]
32. Preclinical safety assessment and pharmacokinetics of gadodiamide injection, a new magnetic resonance imaging contrast agent.
Harpur ES; Worah D; Hals PA; Holtz E; Furuhama K; Nomura H
Invest Radiol; 1993 Mar; 28 Suppl 1():S28-43. PubMed ID: 8486501
[TBL] [Abstract][Full Text] [Related]
33. Cardiac effects of contrast media in MR angiography: evaluation in an experimental model of myocardial ischemia.
Castano M; Cipolla P; Garribba D; Tirone P
Acad Radiol; 1999 Dec; 6(12):719-22. PubMed ID: 10887892
[TBL] [Abstract][Full Text] [Related]
34. Safety assessment of gadopentetate dimeglumine in U.S. clinical trials.
Goldstein HA; Kashanian FK; Blumetti RF; Holyoak WL; Hugo FP; Blumenfield DM
Radiology; 1990 Jan; 174(1):17-23. PubMed ID: 2403679
[TBL] [Abstract][Full Text] [Related]
35. Extravascular toxicity of two magnetic resonance contrast agents. Preliminary experience in the rat.
Cohan RH; Leder RA; Herzberg AJ; Hedlund LW; Wheeler CT; Beam CA; Nadel SN; Dunnick NR
Invest Radiol; 1991 Mar; 26(3):224-6. PubMed ID: 2055727
[TBL] [Abstract][Full Text] [Related]
36. [General toxicity study of gadobenate dimeglumine formulation (E7155) (3)--4-week repeated dose intravenous toxicity study followed by 4-week recovery period in rats].
Aoki T; Sagami F; Tirone P; Morisetti A; Bussi S; Masters RE
J Toxicol Sci; 1999 Nov; 24 Suppl 1():19-39. PubMed ID: 10637778
[TBL] [Abstract][Full Text] [Related]
37. Cardiovascular responses after ionic and nonionic magnetic resonance contrast media in rats with acute myocardial infarction.
Li HT; Saeed M; Wendland MF; Higgins CB
Invest Radiol; 1993 Jan; 28(1):11-9. PubMed ID: 8425847
[TBL] [Abstract][Full Text] [Related]
38. Effects of gadopentetate dimeglumine administration after osmotic blood-brain barrier disruption: toxicity and MR imaging findings.
Roman-Goldstein SM; Barnett PA; McCormick CI; Ball MJ; Ramsey F; Neuwelt EA
AJNR Am J Neuroradiol; 1991; 12(5):885-90. PubMed ID: 1950917
[TBL] [Abstract][Full Text] [Related]
39. Contrast-enhanced MR Angiography of the renal arteries: blinded multicenter crossover comparison of gadobenate dimeglumine and gadopentetate dimeglumine.
Prokop M; Schneider G; Vanzulli A; Goyen M; Ruehm SG; Douek P; Daprà M; Pirovano G; Kirchin MA; Spinazzi A
Radiology; 2005 Feb; 234(2):399-408. PubMed ID: 15616119
[TBL] [Abstract][Full Text] [Related]
40. The effect of Gd-dimeglumine on subcutaneous tissues: a study with rats.
McAlister WH; McAlister VI; Kissane JM
AJNR Am J Neuroradiol; 1990; 11(2):325-7. PubMed ID: 2107714
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
